FeesSafety
Pluang+

Flowers Foods adds Shaun Mara and Ken Plunk as independent directors to boost financial expertise.

Company Fundamentals
04 Nov 2026, 16:00 WIB
PRNewsWire
View Source
Bullish
Flowers Foods adds Shaun Mara and Ken Plunk as independent directors to boost financial expertise.

Flowers Foods announced the election of Shaun P. Mara and Ken Plunk as independent directors effective November 18, 2026, expanding the board to 10 members. Both bring extensive financial and leadership experience, with Mara having held CFO roles at several companies and Plunk bringing expertise from consumer goods and retail sectors. Their appointments aim to strengthen Flowers Foods' financial oversight and support its growth and transformation strategies. This move signals the company's focus on enhancing governance and execution amid evolving market conditions.

Flowers Foods board election news provides context for consumer staples market data. For readers following consumer staples, here is Pluang's market snapshot as of Nov 04, 2026 19:41 WIB: Out of 63 priced US stocks, 50 rose and 9 fell. Notable movers include XXII at USD 0.04 with a -17.81% change and 95% buy orders, CCEP at USD 115.64 up 3.66%, and BF.B at USD 29.90 down 3.28% with 100% sell orders.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
27 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
27 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
27 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
27 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
27 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App